-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Neutral on Biogen, Raises Price Target to $135

Benzinga·08/01/2025 20:16:15
Listen to the news
Citigroup analyst Geoff Meacham maintains Biogen (NASDAQ:BIIB) with a Neutral and raises the price target from $125 to $135.